{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": {
    "pdf_name": "Liu_et_al.__2024_",
    "source_pdf": "data/clinical_files/Liu et al. (2024).pdf",
    "total_pages": 13,
    "total_blocks": 124,
    "total_characters": 39807
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "RIV4 contains 3 times the i d 45 HA/d / ...d",
      "relevance_explanation": "This quote establishes that the recombinant influenza vaccine (RIV4) is a higher-dose vaccine compared to standard-dose egg-based vaccines, which is necessary context for the claim."
    },
    {
      "id": 2,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "relevance_explanation": "This directly supports the claim by stating that the higher-dose recombinant flu vaccine (RIV4) induced higher antibody responses than the standard-dose egg-based vaccines (IIV4) for A (H3N2) virus."
    },
    {
      "id": 3,
      "quote": "For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody ... it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "relevance_explanation": "This quote provides evidence that RIV4 (the higher-dose recombinant vaccine) led to a more robust antibody response than standard-dose egg-based vaccines, specifically for A (H3N2)."
    }
  ],
  "model_used": "gpt-4.1"
}